Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

20. Juni 2018 07:30 ET | Quelle: TG Therapeutics, Inc.

TG Therapeutics and Novimmune SA Announce Global Agreement for Development and Commercialization of a Novel Anti-CD47/ Anti-CD19 Bispecific Antibody

NEW YORK, June 20, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) and Novimmune SA, today announced that the companies have entered into an exclusive global agreement to collaborate on...
18. Juni 2018 12:00 ET | Quelle: TG Therapeutics, Inc.

TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab in Patients with Multiple Sclerosis at the 4th Congress of the European Academy of Neurology

NEW YORK, June 18, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced updated results from the Phase 2 multicenter trial of ublituximab (TG-1101), the Company’s novel...
18. Juni 2018 07:30 ET | Quelle: TG Therapeutics, Inc.

TG Therapeutics, Inc. Presents Phase 2 Data Evaluating Umbralisib in CLL Patients Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy at the 23rd Congress of the European Hematology Association (EHA)

NEW YORK, June 18, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced an oral presentation of clinical data from its ongoing Phase 2 study evaluating umbralisib...
15. Juni 2018 09:17 ET | Quelle: TG Therapeutics, Inc.

TG Therapeutics, Inc. Announces Clinical and Preclinical Data Presentations at the 23rd Congress of the European Hematology Association

NEW YORK, June 15, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the presentation of an integrated analysis of long term safety data of umbralisib (TGR-1202), the...
15. Juni 2018 08:13 ET | Quelle: TG Therapeutics, Inc.

TG Therapeutics, Inc. Announces Oral Presentation of Umbralisib plus Ruxolitinib in Patients with Myelofibrosis at the 23rd Congress of the European Hematology Association

NEW YORK, June 15, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced updated clinical data from its ongoing Phase I study evaluating umbralisib (TGR-1202), the Company’s...
05. Juni 2018 07:30 ET | Quelle: TG Therapeutics, Inc.

TG Therapeutics, Inc. to Present at the Jefferies 2018 Global Healthcare Conference

Presentation scheduled for Thursday, June 7, 2018 at 10:30am ET NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that Michael S. Weiss, the Company’s...
04. Juni 2018 09:00 ET | Quelle: TG Therapeutics, Inc.

TG Therapeutics, Inc. Announces Umbralisib Clinical Data Presentation at the 54th Annual Meeting of the American Society of Clinical Oncology

CHICAGO, June 04, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced updated clinical data from its ongoing Phase 2 study evaluating umbralisib (TGR-1202), the Company’s...
04. Juni 2018 07:30 ET | Quelle: TG Therapeutics, Inc.

TG Therapeutics, Inc. Appoints Adam Waldman as Chief Commercial Officer

NEW YORK, June 04, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the appointment of Adam Waldman as Chief Commercial Officer. Mr. Waldman brings extensive experience...
01. Juni 2018 07:30 ET | Quelle: TG Therapeutics, Inc.

TG Therapeutics, Inc. Recaps Upcoming Data Presentations at the 54th Annual Meeting of the American Society of Clinical Oncology and the 23rd Congress of the European Hematology Association

NEW YORK, June 01, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today recapped the schedule of data presentations at the upcoming 54th Annual Meeting of the American Society of...
17. Mai 2018 09:10 ET | Quelle: TG Therapeutics, Inc.

TG Therapeutics, Inc. Announces Upcoming Data Presentations at the 54th Annual Meeting of the American Society of Clinical Oncology and the 23rd Congress of the European Hematology Association

NEW YORK, May 17, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that abstracts featuring umbralisib (TGR-1202), the Company's once-daily PI3K delta inhibitor, and...

Vorherige Seite

Nächste Seite